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Abstract
Aim: To carry out a systematic review of the available evidence from health decision
makers, patients, and therapists regarding the ability of Baclofen use in decreasing
alcohol withdrawal symptoms to patients in inpatient settings. acute care setting.
Methodology: Systematic searches were carried out on the following databases:
Academic Search Premier, CINAHL, Cochrane and PsycINFO via EBSCO Host,
Embase, MEDLINE via PubMed, and Web of Science. The last search date was May 28,
2019. The search was limited to the last 10 years, i.e., from January 1st, 2010.
Findings: Four studies were included in the final review. The total population was 258
patients. The studies did not report any statistically significant difference between
Baclofen to placebo during the end of the treatment when it comes to decreasing alcohol
withdrawal symptoms and reduction of alcohol intake. There was also not a considerable
difference between baclofen and standard care dropout, adverse events, and anxiety.
Baclofen also increased the frequency of vertigo, dry mouth, and sleepiness.
Conclusions: It was uncertain whether Baclofen improves withdrawal signs and
symptoms and reduces side effects in comparison to placebo or other medicines as the
studies reviewed did not point to any statistical significance. It is recommended that
future reviews assume the meta-analysis approach that can help in measuring the level of
heterogeneity in such studies to effectively examine the extent to which baclofen can be
effective.
Keywords: Alcohol Use Disorder, Baclofen, Efficacy, Safety.
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Baclofen Use in Alcohol Withdrawal Patients in Inpatient Settings:
A Systematic Review
Background/Statement of the Problem
Alcohol use disorder (AUD), or at times referred to as alcoholism, is a pattern of
alcohol consumption that is characterized by the following: (1) being preoccupied with
alcohol, (2) failing to control the level of alcohol use, (3) having to drink more to get the
same effect, (4) continuing to drink even after it leads to problems, and (5) experiencing
withdrawal symptoms when a person wants to stop use or reduce the amount of alcohol
use (Boels et al., 2017). Unhealthy use of alcohol compromises both the users’ safety and
health, which also leads to other alcohol-related problems. In some cases, unhealthy use
of alcohol has been referred to as ‘binge drinking’, which is a drinking pattern in which
an individual consumes five or more alcoholic beverages in less than two hours (Minozzi
et al., 2018). For one to know that they are suffering from AUD, one simply needs to
review whether one’s alcohol consumption leads to repeated distress and functional
problems in his or her life. This can range from mild to severe, but even a mild disorder
can lead to serious issues, making it more important than ever to treat such conditions.
Alcohol use disorder is classified as a behavioral disorder represented by
dysfunctional patterns of alcohol use that can lead to several psychophysical, affective
and cognitive symptoms, as well as serious implications for psychosocial well-being and
health (Minozzi et al., 2018). Alcohol use disorder is reported to be one of the most
widespread psychiatric disorders (Boels et al., 2017). The World Health Organization
(WHO), reported in 2018 that the one-year prevalence of AUDs globally was 4.1%, with

2

the highest prevalence in European nations and North America at 7.5% and 6%,
respectively
Globally, the misuse of alcohol is one of the main health risk factors for such
conditions as epilepsy, homicide, liver disease, motor vehicle accidents, esophageal
cancer, and other intentional injuries (Minozzi et al., 2018). Boels et al. (2017) and
Minozzi et al. (2018) have argued that developing mechanisms for helping AUD patients
reduce alcohol cravings may be one way to help reduce the implications of AUD. The
prescription medication, Baclofen, has been suggested as one method to help AUD
patients in reducing their craving for alcohol (Minozzi et al., 2018 and Boels et al., 2017).
Problem Statement
The treatment of AUD has been dominated by psychological strategies, such as:
psychotherapy (individual or group), behavior therapy, cue exposure, contingency
management, skills training, cognitive behavioral therapy, family, and couple therapy,
etc. Although these methods have been developed as a focused psychological strategy,
their effectiveness has been limited. Minozzi et al. (2018) reviewed 12 randomized
controlled trials (RCT) involving 1128 outpatients from different hospitals, and
concluded that nearly 70% of patients failed to respond to such interventions, and for
those who responded to the treatment, only a small number managed to reduce patient
craving of alcohol (Minozzi et al., 2018). Baclofen, which is a newer treatment option for
AUD, has seen little or no focus in a hospital setting but has received much attention over
the past few years in an outpatient setting. Researchers such as Leggio et al. (2015),
Ponizovsky et al. (2015) and Morley et al. (2014) have yielded conflicting results in their
studies when it comes to Baclofen and its ability to deal with patients’ alcohol cravings.
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The diversity of these findings has sparked a discussion on the potential moderators of
alcohol craving. The purpose of this project is to present a systematic review of the best
available evidence regarding the use of Baclofen in the treatment of alcohol withdrawal
symptoms for inpatients. The outcomes that will be measured in this research include
relapsing, frequency of alcohol use, reduction of amount of alcohol consumption after
using Baclofen, occurrence of adverse events after using Baclofen, dropout from
treatment, and the possibility of anxiety and depression.
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Literature Review
The literature search for this review was performed using the databases Cochrane
and MEDLINE via PubMed. The search terms used were: Alcoholism, Alcohol Disorder,
Alcohol Dependence, Alcohol Overdose, Baclofen and Alcohol, Baclofen Use, Inpatient
Settings, Comorbidity, Randomized Placebo-Controlled Trials, High Dose Baclofen Use,
Addictive Behavior, Clinical Institute Withdrawal, Clinical Trial, Craving, Relapse
Prevention, and GABAb. The search was limited to studies published within the last 6
years as influenced by the evidence-based practice (EBP) approach of only
recommending contemporary interventions.
Alcoholism
Alcoholism refers to a pattern of alcohol consumption, which involves issues
managing consumption, and preoccupation with the next alcohol consumption. Even
when an individual is aware that consumption is leading to problems, they continue to
consume more to achieve the same effect, and experience withdrawal symptoms when
they want to stop or reduce drinking alcohol (Boels et al., 2017). Alcoholism is the fourth
leading cause of preventable death worldwide, after smoking, high blood pressure, and
obesity. A study carried out by the World Health Organization in 2018, revealed that
alcoholism resulted in 3 million deaths in 2016, primarily males, which accounted for
5.3% of all deaths the world. The economic implications of alcoholism in 2010 was $249
billion, or $2.05 per drink (Sacks et al., 2015); and as of 2018 the figure has more than
doubled to $566 billon, or $5.01 per drink (WHO, 2018). The dependence on and misuse
of alcohol has severe health, economic, and social consequences for alcohol abusers, their
families, and the society at large (Fogarty International Center, 2016). Alcohol is a
psychoactive substance that affects every organ of the body. Literature has linked its
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consumption to cancer, injuries, tuberculosis, and hundreds of other persisting conditions
(Boels et al., 2017). Crime, violence, unemployment, and absenteeism are also negative
consequences related to excessive use of alcohol (Boels et al., 2017). Aside from killing
more than 3 million people annually, alcohol consumption is also directly tied to most
disabilities among people aged between 15 and 49 years (Fogarty International Center,
2016). This makes it more important than ever to study how to effectively deal with
alcohol and its complications.
The ethology of alcoholism is multifactorial, including genetic, social,
psychological, and environmental factors (Boels et al., 2017). In recent years, the
phenomenon of craving in alcoholism has also received renewed attention. The ethology
of alcohol craving, and alcoholism, considers alcohol to be a food and drug. Thus, in
essence, the same common appetite mechanism involved in ordinary eating is the same
mechanism involved in alcohol ingestion (Ray et al., 2016). While some people can
regulate their food intake, others cannot; this is same for alcohol ingestion (Ray et al.,
2016). Past studies have suggested at least three likely kinds of alcohol cravings (Jones et
al., 2015; Yamini et al., 2014). The first is unadorned hunger, which is the desire to drink
that is not based on conditioning and cues. For instance, someone who is used to taking
more than 5 bottles per drinking session and reduces to less than 2 bottles per drinking
session is more likely to revert to consuming 5 bottles per drinking session compared to
someone who is used to consuming less than 2 bottles per drinking session (Jones et al.,
2015). The second case relates to cues and conditioning (Yamini et al., 2014). This
concept relates to environmental cues that trigger craving of alcohol or cause discomfort
to alcohol consumers who want to withdraw from alcohol consumption (Yamini et al.,
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2014). The third concept suggests that drinking is an automated process, which makes
controlling it very difficult. These concepts will further be discussed in the next section
of this literature review with regards to their specific theories.
Boels et al. (2017) suggested that some individuals react differently to alcohol
use, which can make some individuals more susceptible to AUD. Some risk factors that
cause people to react different include: a family history of abuse, steady alcohol
consumption over time, beginning alcohol use at an early age, depression, social and
cultural factors, history of Bariatric surgery, and history of trauma (Boels et al., 2017).
Because individuals respond differently to alcoholism, diverse treatment methods have
also been developed that can be tailored to the patient’s needs (Boels et al., 2017).
Treatment can include brief intervention, group or individual counseling, an inpatient
stay program, or an outpatient program. Some of the interventions include detoxification
and withdrawal programs, psychological counseling, oral medication, education, injected
medication, constant healthcare support, spiritual practice, etc. (Boels et al., 2017).
According to Hasin et al. (2016), as stress increases during sobriety, craving may
also increase. In a national epidemiologic survey on alcohol and related conditions by
Hasin et al. (2016), the researchers found that 75% of participants attributed their alcohol
cravings to stress. The researchers recruited participants from the NESARC-III target
population, which is a non-institutionalized civilian population (18+ years). The National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III) is a nationwide
representative survey of more than 46,000 Americans who submitted data on AUDs and
their associated disabilities, as well as saliva samples. The aim of this study was to
provide further understanding of the risk factors, prevalence, health disparities, and costs
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of AUDs. The data, which is available publicly, also includes information on stress and
alcohol consumption. Hasin et al. (2016) found that 56% of the participants attributed
alcohol consumption to stress-related factors.
Theoretical Models of Alcohol Craving
As discussed, in the previous section, people react differently to alcohol
consumption. Accordingly, it is relevant to examine different theoretical models of
alcohol craving to better understand the basis behind the different reactions to alcohol
consumption. Craving refers to the conscious experience of a desire to consume alcohol
(Hasin et al., 2016). Various models explain the basis of craving, which are grouped into
the following classes: phenomenological theories, conditioning theories, and cognitive
theories. Phenomenological theories of craving are mainly descriptive in nature and are
derived from the observations and interviews conducted on clinical addicted patients
(Hasin et al., 2016). Phenomenological theories such as the Loss of Control Theory and
the Unawareness of Compulsion to Drink Theory, both discussed by Drummond (2001),
consider craving to be a symptom of alcoholism where an individual shows signs of
alcohol addiction and obsessive use of alcohol. Drummond (2001) defined alcohol
addiction and obsessive use of alcohol as the consumption of more than 2 drinks in one
hour.
Conditioning theories, on the other hand, include the conditioned withdrawal
model, the conditioned process model, the conditioned drug-like model, the two-process
theory, the incentive sensitization theory, and the cue-reactivity model (Drobes et al.,
2001). These groups of theories differ slightly in terms of the effect of an alcoholic
patient’s withdrawal from alcohol use.

8

Conditioning theories are, however, all derived from the belief that neutral
stimuli in someone’s environment can elicit conditioned responses through a process
termed conditioned learning. Neutral stimuli are stimuli that initially produce no specific
response other than focusing attention (Drobes et al., 2001). Drobes et al. (2001)
proposed that the conditioned responses sparked by such cues, for example an alcohol
advertisement, can lead to alcohol craving. According to conditioning theories, alcohol
withdrawal is negatively affected by the users’ displeasure of the substance used to help
in their withdrawal. This may happen if a patient negatively reacts to the drug is
introduced to help in the withdrawal, for example an allergic reaction to a medication
(Connor et al., 2016). The two-process theory, incentive sensitization theory, and the cuereactivity model argue that alcohol withdrawal is negatively affected by the same
environmental cues, as alcohol advertisements (Drobes et al., 2001). Drobes et al. (2001)
points out that when an individual views an alcohol advertisement it may affect the
withdrawal process. In other words, it may entice them to want to consume again.
The last group of theories that attempt to describe craving experienced in AUD
are known as cognitive theories. Theories in this category include cognitive social
learning theory, cognitive labeling model, dual affect model, dynamic regulatory model,
and cognitive processing model (Nandrino et al., 2014). Cognitive theories are derived
from the belief that in a high-risk situation, e.g., where one of the alcoholic individuals is
faced with a choice of consuming a drink or not, the probability of consuming will rely
on their expectations. Some of these expectations include efficacy expectations and
outcome expectations. Efficacy expectations are the person’s confidence in their ability to
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resist the temptation to consume alcohol, whereas outcome expectations are the person’s
beliefs concerning the consequences of consuming a drink or not (Nandrino et al., 2014).
Non-Pharmacological Treatments for Craving
By examining the possible causes of alcohol craving, it becomes evident that
health care providers should focus attention on both pharmacological and nonpharmacological methods for craving. A multi-faceted approach in managing AUD, and
craving, may provide a more individualized method for successful alcohol withdrawal
treatment. Non-pharmacological interventions are important components of alcohol
craving that can be applied alone or together with medication. Connor et al. (2016) points
out that a combination of both has been found to be more effective in managing AUD
compared to pharmacological treatment alone. Some of the non-pharmacological
treatments of alcohol craving include psychotherapy (individual or group), behavior
therapy, cue exposure, contingency management, skills training, cognitive behavior
therapy, family and couple therapy, etc. (Connor et al., 2016). Psychotherapy is the
verbal interaction between a patient or a group of patients and a therapist, which is aimed
at altering the behavior and feelings of the patients. In AUD, an example of
psychotherapy is Alcoholics Anonymous (AA) (Connor et al., 2016). Cue exposure is the
act of exposing AUD patients to prevention and coping stimuli each time they see
something that relates to alcohol; such stimuli can include pictures of the severe effects of
alcoholism on alcohol abusers (Connor et al., 2016).
Very few people with AUD seek treatment on their own. Studies carried out by
Hasin et al. (2016) and Grant et al. (2015) had comparable results when they concluded
that around 5-15% of people with AUD seek therapeutic interventions voluntarily. Such
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persons are usually taken to therapists by friends or family members, and thus may end
up being less motivated to go through the therapy sessions. Some of these patients never
feel the need of undergoing the therapy sessions, whereas other simply decline.
A review carried out by the Canadian Agency for Drugs and Technologies in
Health (2014) examined compliance rate between pharmacological treatments versus
non-pharmacological treatments when treating AUD. The review, which included 8
reports, found that in an outpatient population, patients tend to comply more with nonpharmacological treatments versus pharmacological treatments. The agency attributed the
low compliance with pharmacological treatments to the decreased supervision granted to
outpatients. This is because non-pharmacological treatments, whether in-patient or
outpatient, still require patients to be physically present with a therapist in order for the
interventions to be administered (Canadian Agency for Drugs and Technologies in
Health, 2014). Another conclusion made by the Canadian Agency for Drugs and
Technologies in Health (2014) was that there have been no clinical trials focusing on the
effectiveness of non-pharmacological interventions alone. Currently the literature only
provides evidence of the studies that have compared pharmacological versus nonpharmacological interventions.
Pharmacological Treatments for Craving
Though non-pharmacological treatments have demonstrated effectiveness,
pharmacological interventions offer alternative methods for patients who suffer from
alcohol craving (Hasin et al., 2016). Pharmacological treatments for craving argue that
the same person may experience different types of cravings depending on the rewards
they get or the coping issues they experience (Grant et al., 2015). Expanding on this
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notion, Saha et al. (2016) adds that the same individual can experience obsessive
rewarding or coping cravings or even a combination of them. Saha et al. (2016) further
points out that reward cravings occur when an individual consumes alcohol to gain the
perceived rewards. Coping cravings, on the other hand, emerge when one consumes
alcohol due to perceived challenges they face while not intoxicated, such as stress (Saha
et al., 2016).
Naltrexone. One of the most well-known pharmacological methods for treating
craving is the use of Naltrexone, which is sold under the brand name ReVia and Vivitrol
(Oslin et al., 2015). Naltrexone helps in reducing alcohol craving within the first three
months of use in nearly 36% of the users, which makes it helpful for curbing alcohol use
in patients (Oslin et al., 2015; Foa et al., 2013). Nonetheless, some of the drawbacks of
naltrexone are that it cannot be used in hepatic disease patients, or in patients with past
cases of depression or suicide attempts because depression is one of the side effects of
Naltrexone (Oslin et al., 2015). Another medication used for withdrawal is Disulfiram,
which works by inhibiting the enzyme acetaldehyde dehydrogenase, thus reducing the
after-effects of alcohol consumption. The use of Disulfiram, however, is limited, as this
medication is self-administered in the outpatient setting. Compliance has been found to
be poor when patients self-administer this medication but is has demonstrated
effectiveness when administered in the clinical setting (Oslin et al., 2015). For example, a
randomized control trial conducted by Foa et al. (2013), found that Disulfiram helped to
reduce alcohol craving in 49% of in-patients, while only reducing alcohol craving in 14%
of the out-patients who self-administered the drug. The study included 165 patients (95
in-patients and 70 out-patients) recruited from the University of Pennsylvania and the
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Philadelphia Veterans Administration. Foa et al. (2013) noted the challenges with selfadministration of this type of medication and claimed that some of the patients at times
skipped or completely stopped using the drugs because of the challenges.
Benzodiazepines. Another common pharmacological treatment for craving is the
use of benzodiazepines. Benzodiazepines are controlled, schedule IV substances that are
only used following a healthcare professional’s recommendation for alleviation of AUD
withdrawal symptoms (AAC, 2019). Whereas many people diagnosed with AUD never
go through severe withdrawal symptoms or complications, benzodiazepines are usually
prescribed during the initial phase of detoxification, as they tend to work best during the
initial phase when alcohol withdrawal symptoms present most strongly. Dixit et al.
(2016) demonstrated this in a review comparing the effectiveness between
benzodiazepines and disulfiram. This review, which included 17 clinical trials published
between 2011 and 2015 concluded that AUD patients tend to be less responsive to
benzodiazepines after three weeks of treatment, and the symptoms are still present.
Investigators in this study point out that benzodiazepines are best used to manage
withdrawal symptoms during the first week or two of treatment, and if the symptoms do
not subside, the intervention should be changed (Dixit et al., 2016).
Alternative Pharmacological AUD Treatment: Baclofen
While the pharmacological and non-pharmacological treatments discussed above
have been approved for treating AUD patients, their clinical and non-clinical use is rather
limited by different factors. As previously stated, even though disulfiram reduces alcohol
craving, its ability to cause depression renders it a dangerous medication for patients with
past depression issues (Minozzi et al., 2018). Other substances, such as naltrexone and
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benzodiazepines, have been ruled as safe and effective among AUD patients, but the high
variation in response to treatment suggests that some patients might not benefit from this
intervention (Chaignot et al., 2018). An alternative, such as Baclofen, offers promise in
recent research because this medication lacks any of the unwanted adverse effects and
addictive properties discussed earlier of such treatments as Benzodiazepines, Disulfiram,
and Naltrexone.
Baclofen. Baclofen is an agonist of the γ-aminobutyric acid type B receptor that is
sold under the brand names Lioresal and Kemstro. It was originally approved for use in
spasticity-related neurological illnesses but has only recently emerged as a treatment
option for AUD (Boels et al., 2017). Baclofen has been investigated as an option for
treating alcohol craving since the early 2000s after a group of researchers found that
baclofen prevented withdrawal symptoms in rats (Minozzi et al., 2018). This seminal
work has since led to the investigation, and possible use for this treatment in human
beings. For example, a single-patient case report presented by Perogamvros et al. (2015)
concluded that the administration of baclofen 10mg every 8 hours improved the patient’s
Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score. The case report
included a 61-year-old patient with AUD who was referred to the sleep laboratory in an
unnamed university hospital in Basel after previously incurring three road accidents due
to sleepiness.
In a cohort report study consisting of 165,334 patients aged between 18 and 70
years, Chaignot et al. (2018) showed that baclofen was effective in reducing Delirium
Tremens (DT) among patients in the ICU. Delirium Tremens is one of the most severe
form of alcohol withdrawal, which is manifested by altered mental status and sympathetic
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overdrive, which can lead to cardiovascular collapse. The participants were recruited
from the French national health insurance information system database (SNIRAM), and
had to have an initial diagnosis of AUD, with baclofen as the treatment intervention. The
researchers compared DT to a placebo treatment. The number of hospital days was
significantly lower among DT patients who were treated with baclofen (M=23 days)
compared to those treated with a placebo (M=39 days). Most notably, the death rate was
also significantly lower among the patients who used baclofen (9%) compared to those
who received the placebo treatment (15%) (Chaignot et al., 2018).
While several open-label trials, case series, and case reports have shown the
effectiveness of Baclofen in AUD patients (Brennan et al., 2013; Reynaud et al., 2017;
Rolland et al., 2014), some randomized controlled trials (RCTs) (Farokhnia et al., 2017;
Ponizovsky et al., 2015), have shown conflicting findings. For instance, in Farokhnia et
al. (2017), 80 AUD patients received 30 mg/day of Baclofen or a placebo for 12 weeks in
addition to eight sessions of a comprehensive psychological intervention. Researchers
found no difference between baclofen and placebo in the percentage of heavy drinking
days, time to lapse, and abstinent days (Farokhnia et al. (2017). Reynaud et al. (2017)
also compared the effectiveness of 30 mg/day of baclofen and a placebo in the treatment
of AUD for 12 weeks as well. The authors found that baclofen significantly reduced the
number of drinks per drinking day.
As noted earlier, researchers have found it difficult to assess the efficacy of
interventions such as baclofen in outpatients due to lack of compliance with selfadministration (Beraha et al., 2016; Cooney et al., 2019). However, a treatment such as
this may still be beneficial if employed in the inpatient setting. Therefore, the purpose of
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this review was to systematically review the use of baclofen in the inpatient setting for
AUD patients during withdrawal.
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Theoretical Framework
This review utilized the PRISMA framework discussed by Stewart et al. (2015).
The word PRISMA, which stands for Preferred Reporting Items for Systematic reviews
and Meta-Analyses, comprises of a four-phase flow diagram, which guides researchers
on how to improve on their reporting of systematic reviews and meta-analyses (Stewart et
al., 2015). Even though the checklist recommends that researchers mainly use RCTs
when conducting their systematic reviews, the PRISMA framework can also be used in
reviewing other types of research methods for evaluation of data reporting. The fourphase flow diagram that was adapted from Stewart et al. (2015) is attached in Figure 1
below.
The procedure for the literature research is illustrated in Fig. 1 below. The process
began by searching multiple databases for the necessary literature. In the search results,
duplicates were removed, and the titles and abstracts of the remaining studies were
reviewed to see if they met the inclusion criteria. Once the studies that did not meet the
inclusion criteria based on their titles and abstracts were excluded, the remaining studies
were fully reviewed and those that did not meet the inclusion criteria based on their
objectives, designs, and findings were also excluded. These steps are illustrated in figure
1 below:
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Identification

PRISMA 2009 Flow Diagram

Records identified through
database searching
(n = )

Additional records identified
through other sources
(n = )

Eligibility

Screening

Records after duplicates removed
(n = )

Records screened
(n = )

Records excluded
(n = )

Full-text articles assessed
for eligibility
(n = )

Full-text articles excluded,
with reasons
(n = )

Included

Studies included in
qualitative synthesis
(n = )

Studies included in
quantitative synthesis
(meta-analysis)
(n = )

Figure 1. Four-phase flow diagram for preferred reporting items for systematic reviews
and meta-analyses (Liberati et al., 2009)
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Method
Purpose
The purpose of this project was to present a systematic review of the best
available evidence regarding the use of baclofen in the plan of care in the treatment of
alcohol withdrawal symptoms for patients within an acute care hospital setting.
Inclusion/Exclusion Criteria
The inclusion criteria for studies included was as follows: (a) Alcohol withdrawal;
(b) January 1, 2013 onward; (c) English language; (d) Intervention utilizing Baclofen; (e)
Inpatients aged > 18 and diagnosed with alcohol withdrawal disorder; and (f)
Randomized controlled trials (RCT) studies. The exclusion criteria for the literature
search was: (a) Not published in English language; (b) Patients younger than 18 years
old; (c) Outpatients; and (d) Non-RCT’s.
Search Strategy
The literature search was performed using the databases Cochrane and MEDLINE
via PubMed. The search terms used were: Alcoholism, Alcohol Disorder, Alcohol
Dependence, Alcohol Overdose, Baclofen and Alcohol, Baclofen Use, Inpatient Settings,
Comorbidity, Randomized Placebo-Controlled Trials, High Dose Baclofen Use,
Addictive Behavior, Clinical Institute Withdrawal, Clinical Trial, Craving, Relapse
Prevention, and GABAb. The search was limited to studies published within the last 6
years as influenced by the evidence-based practice (EBP) approach of only
recommending contemporary interventions.
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Data Collection
Descriptive data collected from each study was summarized in study description
tables (Appendix B), which specifies the researcher names, date of publication, aim(s),
design, sample, setting, and methods. Additionally, a second set of tables, labeled
‘Outcome Data Collection’ (Appendix C) display data collected regarding outcomes
under investigation in this review. These include: (1) relapsing, which was measured by
the number of patients who returned to drinking during the cause of the study and the
follow-up; (2) frequency of alcohol use, which was measured by the percentage of
abstinent days at the end of treatment; (3) the amount of alcohol consumption, which was
measured by the number of drinks per drinking occasion or drinking day; (4) occurrence
of adverse events after implementing the intervention such as fatigue and tiredness,
insomnia, pain, vertigo, dizziness, drowsiness, sedation, dry mouth, and constipation; (5)
dropout from treatment, and (6) possibility of anxiety and depression.
Critical Appraisal
The assessment of the quality and bias present in all retrieved studies was done
using the Critical Appraisal Skills Program (CASP) tool (Appendix D). The CASP tool
addresses such factors as sequence generation, allocation concealment, participants’
blinding, blinding of assessors, incomplete outcome data, and selective reporting
(Higgins et al., 2017). The Critical Appraisal Skills Program was developed to help
researchers judge the quality of randomized controlled trials (RCTs) based on the factors
mentioned above (Higgins et al., 2017). These factors are usually judged as either high,
low, or unclear depending on how the people who carry out RCTs report on them in their
studies. The importance of the tool is that it offers a universally agreed upon method of
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judging RCTs to know whether to implement the evidence uncovered (Higgins et al.,
2017).
Data Synthesis
All studies included within this systematic review were evaluated to compare the
differences and similarities using a narrative approach. A narrative of the findings is
presented in the next section to discuss the findings of the data synthesis. The outcomes
from each individual trial are combined through a thematic analysis, thus the review was
not be able to measure any degree of heterogeneity, which can only be achieved through
a meta-analysis. A thematic approach is where one study is the leading themes arising
from the outcomes of each trial and reports these themes.
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Results
Search Results
The databases search retrieved 199 studies. Upon further assessment, 98 duplicates
were removed, leaving a total of 101 studies. Eighty-seven more studies were excluded
after a review of their title and abstracts. The full texts of the remaining 14 studies were
assessed and an additional ten were excluded due to the following: they are awaiting
classification, studies are ongoing, the study objectives do not meet this review’s
inclusion criteria, the study designs do not meet this review’s inclusion criteria. In the
end, a total of 4 studies were included in this review. A flow diagram of the procedure
that was followed to exclude 195 studies from the review and include the selected four is
outlined in Appendix A.
Individual Study Description
The aim of a study conducted by Heppe et al. (2019) (Appendix B-1) was to
determine if severity of AWS decreased in hospitalized patients who received baclofen in
their care. This study was a double blind, placebo controlled, randomized trial design.
The study was carried out at Denver Health, a university-affiliated, urban, public, safetynet hospital. The study involved 101 medical inpatients who were at risk for developing,
or presented with, mild AWS. Patients were grouped into two groups who received oral
medication of either baclofen 10 mg, (n=50) or placebo (n=51) every eight hours for five
days or until hospital discharge. All participants also received symptom driven
benzodiazepine as directed by Severity of Ethanol Withdrawal Scale SEWS protocol. The
study measurements included: the proportion of patients progressing to moderate or
severe AWS, and difference in mean SEWS assessment scores at 24h, 48h, and 72h
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between groups; peak and cumulative dosage of benzodiazepines over 72h postenrollment (Heppe et al., 2019).
The purpose of the study by Lyon et al. (2011) (Appendix B-2) study was to
determine the effect of gamma- Aminobutyric acid (GABA)-B agonist baclofen on the
course of acute symptomatic AWS. The research assumed a prospective, randomized,
double-blind placebo-controlled clinical design. It was carried out in two tertiary-care
hospitals in Duluth, Minnesota. The study involved 31 inpatient adults who were
admitted for any reason, including AWS, and judged to be at high risk for AWS. Patients
were grouped into two groups who received oral medication of either: baclofen 10 mg,
(n=18) or placebo (n=13) every eight hours for 72 hours or until hospital discharge. All
participants also received symptom driven lorazepam as directed by CIWA-AR protocol.
Measurements included: AWS severity was assessed using the Clinical Institute
Withdrawal Assessment of Alcohol Scale, revised (CIWA-AR) and Lorazepam dose was
monitored every eight hours for 72 hours or until hospital discharge.
The aim of the study by Girish et al. (2016) (Appendix B-3) was to compare the
efficacy and tolerability of baclofen with chlordiazepoxide in uncomplicated AWS. The
study assumed a randomized, open-label, standard controlled, parallel group study of
baclofen, and chlordiazepoxide in AWS design. The study was carried out in a tertiarycare hospital in India. It involved 60 inpatient adults who were admitted for
uncomplicated AWS. Patients were grouped into two groups who received oral
medication of either baclofen 30 mg, (n=30) or chlordiazepoxide 75 mg (n=30) for 9 days
in decremented fixed dosage. Lorazepam was used as a rescue medication.
Measurements included: CIWA-AR to assess clinical efficacy and Clinical Global
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Impression scores, symptom-free days, and subject satisfaction scores were used as the
secondary efficacy parameters.
The purpose of the study by Gulati et al. (2019) (Appendix B-4) was to compare
the efficacy of baclofen and benzodiazepine (lorazepam) in reducing symptoms of AWS.
The study assumed a single-center, randomized, open-label design. It was carried out in
an acute care setting in the Department of Psychiatry, GMCH, Chandigarh, in India. It
involved 66 patients with the diagnosis of alcohol dependence as per ICD-10 criteria
were enrolled. Patients were grouped into two groups who received oral medication of
either: baclofen 10 mg, (n=30) 3 times or lorazepam 8-12 mg (n=30). The patients
received B1 (100 mg/day through intramuscular route) and psychotherapeutic
interventions. Measurements included: reduced severity of alcohol dependence as
measured by the Severity of Alcohol Dependence Questionnaire (SAD-Q) and alcohol
withdrawal was measured using the CIWA-AR.
Critical Appraisal
As earlier discussed in the methodology, the risk of bias was assessed using the
CASP tool as recommended by Cochrane. For a tabular summary of the bias of the 4
studies, see Appendix D. All studies had low risks when it came to random sequence
generation, implying that the sample population was randomized. One of the 4 studies
(Heppe et al., 2019) did not report on the group allocation, implying the risk was unclear
in that study, while the remaining confirmed to conceal the allocation of groups. All the 4
studies confirmed to blind the participants and assessors to the objective outcomes,
implying that the risk was low. Only two did not report blinding of the subjective
outcomes, implying that the risk was unclear (Girish et al., 2016; Gulati et al., 2019). The
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outcome blinding was thus fairly at low risk. Only one study failed to report on dropouts,
missing data, and thus were judged as unclear (Lyon et al., 2011). All the 4 studies
reported all outcomes, implying that there was no selective reporting.
Cross Study Analysis
Study Characteristics
The cross-study analysis table (Appendix E) demonstrates the primary and
secondary outcomes investigated for each study. This review included four randomized
controlled trials (RCTs) with a total of 258 patients. The mean sample size was 64.5
participants, with a range of 31 participants (Lyon et al., 2011) to 101 participants (Heppe
et al., 2019). The mean participant age was 42 years across all studies and included a
majority of more men when compared to women. All the participants had to have been
diagnosed of alcohol use disorder and who were currently drinking. Two of the studies
were carried out in university hospitals in the United States (Heppe et al., 2019; Lyon et
al., 2011), while the other two were carried out in India (Girish et al., 2016; Gulati et al.,
2019). The outcome measures included in the 4 studies were as follows: (1) relapsing, (2)
frequency of alcohol use, (3) amount of alcohol consumption, (4) occurrence of adverse
events, (5) dropout from treatment, (6) anxiety and depression.
Interventions
All studies used different doses of Baclofen: in Lyon et al. (2011) (between 30 mg
and 270 mg per day), in Heppe et al. (2019) (between 30 mg and 60 mg per day), in
Girish et al. (2016) (between 30 mg and 150 mg per day), and Gulati et al. (2019) (30 mg
per day). The mean duration of intervention was 18.1 weeks, and mean duration for
studies was 19.9 weeks.
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Major Outcomes
Some of the themes that were extracted from the findings of the 4 studies included: (1)
relapsing, (2) frequency of alcohol use, (3) amount of alcohol consumption, (4)
occurrence of adverse events, (5) dropout from treatment, (6) anxiety and depression.
Relapsing. Relapsing was measured by the number of patients who returned to
drinking during the course of the study and the follow-up (Lyon et al., 2011; Heppe et al.,
2019; Girish et al., 2016). These studies, which had a combined total of 192 patients, did
not report any difference between the baclofen group and standard care (placebo) group,
implying that both baclofen and standard care can influence one’s ability of relapsing.
Frequency of Alcohol Use. Frequency of alcohol use was measured by the
percentage of abstinent days at the end of treatment. Only 1 of the 4 studies (Lyon et al.,
2011) found a statistically significant reduction (P = 0.002) in the frequency of use,
implying that baclofen can reduce the frequency one’s alcohol use. One clinical trial
(Heppe et al., 2019) reported the main percentage of days abstinent for each group, but
the researchers did not provide the SD values; the mean percentage of days abstinent was
62.6% for the baclofen patients, and 46.1% for the placebo patients. The rest of the
studies never found any difference between the baclofen group and placebo group; this
means that both baclofen and standard care can influence one’s frequency of alcohol use.
Amount of Alcohol Consumption. The amount of alcohol consumption was
measured by the number of drinks per drinking occasion or drinking day. Two studies
involving 131 participants found that baclofen tends to increase drinks per drinking
occasion as compared to the placebo group (Heppe et al., 2019; Lyon et al., 2011). One
other study involving 66 participants (Gulati et al., 2019) did not report any difference
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between the baclofen group and placebo group, implying that both baclofen and standard
care can have an impact on one’s amount of alcohol consumption.
Occurrence of Adverse Events. Adverse events were measured by the number of
participants with at least one side effect after the end of the treatment. Some of the
adverse events measured include: fatigue and tiredness, insomnia, pain, vertigo,
dizziness, drowsiness, sedation, and dry mouth (Gulati et al., 2019; Heppe et al., 2019),
including constipation as measured in Lyon et al. (2011) and Girish et al. (2016). It is
important to remember that the total number of participants accounted for in these studies
was 258. There was no difference between the baclofen group and placebo group in the
abovementioned adverse events aside from dry mouth, sleepiness, vertigo.
Dropout from Treatment. This measure was present in all the 4 studies; all of
them reported no difference between the baclofen group and placebo group when it came
to drop out from the treatment. This meant that both baclofen and standard care can
equally influence the decision of dropping out from the treatment. Furthermore, there was
no statistically significant difference in the number of patients who dropped out of the
studies due to adverse events in both the control and intervention groups.
Anxiety and Depression. Two studies with a total of 145 patients used different
scales to measure the level of anxiety and depression between the baclofen and placebo
groups (Heppe et al., 2019; Lyon et al. 2011). None of the studies reported any difference
between the two groups when it comes to anxiety, but Lyon et al. (2011) found that
baclofen tends to reduce the level of depression among patients. This is one of the
positives of baclofen that was found during the review of the 4 studies.
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Summary and Conclusions
The aim of this research was to offer a systematic integration of the available
evidence from health decision makers, patients, and therapists regarding the ability of
baclofen in decreasing alcohol withdrawal symptoms to AUD patients in an acute care
setting. The treatment of AUD was in the past dominated by psychological strategies, and
even if methods from different therapeutic and theoretical backgrounds have been
developed, the effectiveness of these methods are limited. A high number of patients fail
to respond to such interventions, and for those who do, only a small number of them
manage to maintain their abstinence (Minozzi et al., 2018). Baclofen as one of the
treatment options for AUD has received much attention over the years. Systematic
searches were carried out on different databases and four randomized controlled trials on
baclofen were retrieved. A summary of the findings from the studies is presented in the
next section.
This review included a total of four randomized controlled trials with 258
participants and a minimum study duration of 19.9 weeks. All the four studies compared
baclofen to placebo (standard care), but they rarely reported on any statistically
significant superiority between baclofen to placebo during the end of the treatment when
it comes to reduction of withdrawal symptoms and drinking. Furthermore, this review
found no considerable difference between baclofen and standard care dropout, dropout
because of adverse events, anxiety, and number of participants with more than one
adverse event that was measured.
The current review employed a narrative approach to determine these findings.
None of the four studies pointed to a significant difference between baclofen and
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standard care. Baclofen was found to be similar to standard care in ensuring continuous
abstinence and reducing drinking amount and frequency. The findings of this systematic
review did not indicate a conclusive implication when using baclofen to treat alcohol use
disorder. Additionally, no support was found for the application of baclofen as a first-line
treatment option for AUD patients. It is worth mentioning, however, that baclofen was
found to significantly reduce the level of depression among patients compared to the
placebo group (Heppe et al., 2019). Unfortunately, baclofen use also increased the
frequency of vertigo, dry mouth and sleepiness (Lyon et al. 2011). Nonetheless, the
sleepiness result was derived from a study (Lyon et al., 2011) with only 30 participants.
Even though RCTs seemed promising, the evidence they present currently cannot be fully
relied upon when it comes to treating AUD patients.
The findings of this research are similar to the findings of De Beaurepaire et al.
(2019), Garbutt (2018), and Farokhnia et al. (2017), in which results likewise did not
point to any benefit of using baclofen to manage AUD. According to De Beaurepaire et
al. (2019), while baclofen has had some positive results in some studies, controversies
still exit regarding dosing, efficacy and safety concerns. De Beaurepaire et al. (2019)
concluded that AUD is ineffective in patients with comorbid conditions, including
psychiatric issues, bipolar affective disorder, anxiety, liver disease, epilepsy, respiratory
diseases, and Parkinson’s Disease. In Garbutt (2018), frequency of alcohol use was
measured by the percentage of abstinent days at the end of treatment. Garbutt’s research
found no difference between the baclofen group and placebo group, indicating no
difference between baclofen and standard care in influencing frequency of alcohol use.
Finally, in Farokhnia et al. (2017) anxious alcohol-dependent individuals (n = 34) were
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randomized to baclofen and placebo groups for a period of 1 year. The outcomes of this
study included total amount of alcohol self-administered, alcohol craving, mood and
anxiety symptoms, and subjective responses to alcohol intake. According to Farokhnia et
al. (2017), self-administered intake was not significantly different in the baclofen group
and placebo group. Alcohol craving and anxiety symptoms, however, were better in the
baclofen group. Overall, the findings of this study indicate that baclofen might not be
effective when it comes to the reduction of withdrawal symptoms. More research
regarding management of depression, consumption amount and abstinence days in the
treatment of AUD is warranted.
Limitations
Some of the major limitation of the current research included its use of only four
studies. The use of only four studies might not give a true reflection of the effectiveness
of baclofen on AUD patients, however, RCTs were the only design types included in this
systematic review. RCTs are considered to have the most reliable evidence when it comes
to evidence-based practice because of the randomization and blinding nature of such
studies. Furthermore, all the patients in the four studies were admitted for AUD. Also, the
studies were evaluated using a critical appraisal approach, thus increasing the strength of
evidence. The differences of the outcomes used in assessing the effectiveness of the
reviewed studies served as the main limitation of this research. This highlights the fact
that different outcomes are established in alcoholism research and demonstrates the lack
of consistency in determining which treatments are most successful.
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Recommendations and Implications for Advanced Nursing Practice
This section will provide the recommendations and implications of the findings of
this research on nursing practice and education.
Implications for Practice
The outcomes of this research did not point to a significant difference between
baclofen and placebo. All of the studies reviewed showed that baclofen was similar to
placebo in terms of maintaining continuous abstinence and reducing drinking frequency
or amount of drinking. The cross-study analyses of primary studies did not point to any
positive implication of baclofen in the treatment and management of AUD. Additionally
findings did not support the application of baclofen as a first-line treatment for AUD
patients. Though some RCTs have suggested promising outcomes the current evidence
regarding use of baclofen as a first-line treatment is still uncertain.
Implications for Research
To better understand the inconsistency of effects shown in this research factors
such as dosing schedules, severity of AUD, treatment setting, and status of drinking at the
start of the treatment may determine efficiency. One factor that needs special attention in
further studies is the titration of dose, to achieve the best therapeutic response. Titration
regimes can be beneficial compared to fixed dosing of baclofen in further clinical trials,
because of the high individual variation of effective doses (Rolland et al., 2014).
Furthermore, to attain the correct implementation of treatment and ‘fairness of testing’,
participants’ compliance needs to be monitored to ensure that dosing schedules are
strictly followed.
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Another issue that needs to be addressed is blinding during treatment, which can
increase the level of bias. Even though the four studies included in this review practiced
some level of blinding, such as: allocation concealment, blinding of personnel, or
blinding of participants, adverse effects can reveal a participant’s research treatment
assignment. The application of active placebo elements that mimic adverse events of
baclofen can prevent an overestimation of effects through response bias, differential
attrition, and/or placebo effects (De Beaurepaire et al., 2019). If an inert placebo is
applied, testing of blinding integrity by questioning participants about their perceived
group allocation can be an easier method that paves the way for retrospective assessment
of blinding integrity (Agabio et al., 2018). Therefore, there is a need to further explore
the efficacy and safety of baclofen and identify potential moderators and mediators of
baclofen’s implications on alcohol use.
Recommendations for Education
Compared with placebo, baclofen was noted to make little to no difference to
patients who experienced adverse events, dropped out of the treatment, and the time
taken for recovery. Also, baclofen made little difference to the number of patients who
relapsed as well as the amount of alcohol the consumed after the treatment. Furthermore,
the main intervention made little to no difference in the number of days the patients
stayed alcohol-free. Also, baclofen might increase the amount of alcohol used, measured
by number of drinks per drinking days, which may lead to adverse events such as
depression, numbness, somnolence, muscle rigidity. However, there was no significant
difference when comparing baclofen and placebo. Greater research is needed in the area
of more effective interventions in order to help AUD patients fully recover.
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Appendices
Appendix A – PRISMA Flow Diagram

Figure 1: PRISMA Flow Diagram
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Appendix B
Table B-1
STUDY DESCRIPTION
Heppe, D. B., Keniston, A., Bendelow, T., McBeth, L., Waring, S., Lyon, J., & Albert, R. K. (2019). Reducing the severity of alcohol
withdrawal with oral baclofen: a randomized controlled trial. Addiction Research & Theory, 27(3), 220-225.
AIM/PURPOSE DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
To determine
whether, after 72
hours of
admission, fewer
patients
hospitalized on
Internal
Medicine
services who
were at risk for
AWS after
applying
baclofen in their
care

A double blind,
placebo
controlled,
randomized trial

Denver Health,
a universityaffiliated, urban
public safety-net
hospital

101 medical
inpatients who
were at risk for
developing, or
presented with,
mild AWS.

Patients were
grouped into two
groups who received
oral medication of
either:
1. Baclofen 10 mg,
(n=50) or
2. Placebo (n=51)
every eight hours for
five days or until
hospital discharge.
All participants also
received symptom
driven
benzodiazepine as
directed by SEWS
protocol.

Measurements included:
- The proportion of patients
progressing to moderate or
severe AWS
- Difference in mean SEWS
assessment scores at 24h, 48h,
and 72h between groups; peak
and cumulative dosage of
benzodiazepines over 72h
post-enrollment.
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Appendix B
Table B-2
STUDY DESCRIPTION
Lyon, J.E., Khan, R.A., Gessert, C.E., Larson, P.M. and Renier, C.M., 2011. Treating alcohol withdrawal with oral baclofen: A
randomized, double-blind, placebo-controlled trial. Journal of hospital medicine, 6(8), pp.469-474.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
To determine the
effect of gammaAminobutyric acid
(GABA)-B agonist
baclofen on the
course of acute
symptomatic AWS

Prospective,
randomized,
double-blind
placebo-controlled
clinical study

Two tertiary-care
hospitals in
Duluth, Minnesota

31 inpatient adults Patients were grouped
Measurements
who were admitted into two groups who
included:
for any reason,
received oral
- AWS
including AWS,
medication of either:
severity was
and judged to be at 1. Baclofen 10 mg,
assessed
high risk for AWS
(n=18) or
using the
2. Placebo (n=13)
Clinical
every eight hours for
Institute
72 hours or until
Withdrawal
hospital discharge.
Assessment
of Alcohol
All participants also
Scale,
received symptom
Revised
driven lorazepam as
(CIWA-AR)
directed by CIWA-AR
- Lorazepam
protocol.
dose was
monitored
every eight
hours for 72
hours or
until
hospital
discharge
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Appendix B

Table B-3
STUDY DESCRIPTION
Girish, K., Reddy, K. V., Pandit, L. V., Pundarikaksha, H. P., Vijendra, R., Vasundara, K., ... & Shruthi, R. (2016). A randomized, open-label,
standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal
syndrome. Biomedical journal, 39(1), 72-80.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
To compare the efficacy
and tolerability of
baclofen with
chlordiazepoxide in
uncomplicated AWS.

A randomized,
open-label,
standard
controlled, parallel
group study of
baclofen, and
chlordiazepoxide in
AWS

A tertiary-care
hospital in India

60 inpatient adults
who were admitted
for uncomplicated
AWS

Patients were grouped
Measurements included:
into two groups who
- The researchers
received oral
employed the
medication of either:
Clinical Institute
1. Baclofen 30 mg,
Withdrawal
(n=30) or
Assessment for
2. Chlordiazepoxide 75
Alcohol-Revised
mg (n=30) for 9 days
Scale (CIWA-AR) to
in decremented fixed
assess clinical
dosage.
efficacy
- Clinical Global
Lorazepam was used as a
Impression scores,
rescue medication.
symptom-free days,
and subject
satisfaction scores
were used as the
secondary efficacy
parameters
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Appendix B

Table B-4
STUDY DESCRIPTION
Gulati, P., Chavan, B. S., & Sidana, A. (2019). Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome.
Indian journal of psychiatry, 61(1), 60.
AIM/PURPOSE
DESIGN
SITE
SAMPLE
METHODS
PROCEDURES
To compare the efficacy of
baclofen and benzodiazepine
(lorazepam) in reducing
symptoms of AWS.

A single-center,
randomized, openlabel study.

An acute care
setting in the
Department of
Psychiatry, GMCH,
Chandigarh, in India

66 patients with the Patients were grouped
Measurements
diagnosis of alcohol into two groups who
included:
dependence as per
received oral medication - Reduced
ICD-10 criteria
of either:
severity of
were enrolled
1. Baclofen 10 mg,
alcohol
(n=30) 3 times pera or
dependence
3. Lorazepam 8-12 mg
as measured
(n=30).
by the
Severity of
The patients received B1
Alcohol
(100 mg/day through
Dependence
intramuscular route) and
Questionnaire
psychotherapeutic
(SAD-Q)
interventions.
- Alcohol
withdrawal
was measured
using the
(CIWA-AR).
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Appendix C
Table C-1
OUTCOME DATA COLLECTION TABLE
All Patients (N =101)

Heppe et al. (2019)
Baclofen (N = 50)

Placebo (N = 51)

Progression to
moderate or severe
AWS within 72 h

n = 29 (29%)

n = 13 (26%)

n = 16 (31%)

P value
0.5507

Highest SEWS score
within 72 h,

n = 6 (± 4 SD)

n = 6 (± 4 SD)

n = 6 (± 4 SD)

0.6230

M: 11mg (± 3 SD)

M: 12mg (± 7 SD)

0.1432

M: 66mg (± 51SD)

M: 85mg (± 63 SD)

0.1362

Highest inpatient
M: 11mg (± 6 SD)
dosage of
benzodiazepines
(mg) during the 72h
following
enrollment
Cumulative inpatient M: 76mg (± 58 SD)
dosage of
benzodiazepines
(mg) over the 72] h
following
enrollment
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Appendix C

Table C-2
OUTCOME DATA COLLECTION TABLE
Lyon et al. (2011)
Baclofen (N = 18)

Placebo (N = 13)

Progression to moderate or severe AWS within 72 h

n = 18 (42%)

n = 13 (35%)

P value
0.004

Dosages of lorazepam > 20 mg over 72h following enrollment

n=1

n=7

0.004

Dosages of lorazepam >50 mg over the 72h following enrollment

n=0

n=4

0.023

Cumulative dosage of lorazepam (mg) over the 72 h following
enrollment

0-39mg

1-1035mg
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Appendix C
Table C-3
OUTCOME DATA COLLECTION TABLE

Study Group
Baclofen
(n=30)
Chlordiazepoxide
(n=30)

Girish et al. (2016)
Total CIWA-AR scores DAY 1
Total CIWA-AR scores DAY 9
M=23.60 ± 6.483
M=1.133 ± 0.730

p value
p = 0.475

M=23.90 ± 7.038

M=0.133 ± 0.434

48

Appendix C
Table C-4
OUTCOME DATA COLLECTION TABLE

Study Group
Baclofen
(n=34)
lorazepam
(n=32)

Gulati et al. (2019)
Total CIWA-AR scores DAY 1
Total CIWA-AR scores DAY 9
M=15
**M=0
M=40

** Presented Graphically by authors.

**M=0

p value
None
provided
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Appendix D

CASP Evaluation
Scale

Girish et al. (2016)

Heppe et al. (2019)

Gulati et al. (2019)

Random Sequence
Allocation Concealment
Blinding of Participants – Objective
Outcomes
Blinding of Participants – Subjective
Outcomes
Blinding of Assessors – Objective Outcomes
Blinding of Assessors – Subjective Outcomes
Incomplete Outcome
Selective Reporting
Score

+
+
+

+
+
+

+
+
+

Lyon et al.
(2011)
+
+
+

+

+

+

+

+
+
+
7

+
+
+
7

+
+
+
+
8

+
+
+
+
8
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Appendix E

Cross-Study Analysis
AUTHOR /
YEAR

COMPARISONS OR
PROTOCOL OF STUDY

Heppe et al.
(2019)

Main intervention: baclofen
Comparison: placebo

N/A

Lyon et al.
(2011)

Main intervention: baclofen
Comparison: placebo

N/A

Progression to moderate or
severe AWS within 72 h
Baclofen n = 18 (42%)
Placebo n = 13 (35%)

N/A

Girish et al.
(2016)

Main intervention: baclofen
Comparison:
chlordiazepoxide

Baclofen M=23.60 ± 6.483
Chlordiazepoxide M=23.90 ±
7.038

N/A

Gulati et al.
(2019)

Main intervention: baclofen
Comparison: Lorazepam

Total CIWA-AR scores DAY
1
Baclofen M=15
Chlordiazepoxide M=40

N/A

Total CIWA-AR scores
DAY 9
Baclofen M=1.133 ±
0.730
Chlordiazepoxide
M=0.133 ± 0.434
Total CIWA-AR scores
DAY 9
Baclofen **M=0
Chlordiazepoxide
**M=0

** Presented Graphically by authors.

Total CIWA scores
Day 1

Progression to Moderate or
Severe AWS within 72 h
Day 3
Baclofen n = 13 (26%)
Placebo n = 16 (31%)

Total CIWA scores
Day 9
N/A

